No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Clene Secures $10M Debt Facility to Enhance Position
Press Release: Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Promising Prospects for Clene's ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory Progress
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway
Clene Gains FDA Support for ALS Treatment Approval